Abstract
ObjectivesAliskiren is a novel renin-angiotensinaldosterone system (RAAS) inhibitor, the combination therapy of aliskiren andamlodipine for blood pressure control have been reported recently. The primary objective of this analysis is to...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
